Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
GSK-690693
GSK690693 |
| gptkbp:CASNumber |
937174-76-0
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C21H22N8O2S
|
| gptkbp:hasSMILES |
CC1=NC(=C(S1)N2CCOCC2)C3=NC(=NC=N3)NCCC4=CN=CN4
|
| gptkbp:hasTherapeuticApplication |
cancer research
oncology |
| https://www.w3.org/2000/01/rdf-schema#label |
ESI-09
|
| gptkbp:isAKinaseInhibitor |
true
|
| gptkbp:IUPACName |
N-(3-(1H-imidazol-4-yl)propyl)-4-(2-methyl-4-morpholin-4-yl-thiazol-5-yl)pyrimidin-2-amine
|
| gptkbp:mechanismOfAction |
AKT inhibitor
|
| gptkbp:molecularWeight |
450.52 g/mol
|
| gptkbp:PubChem_CID |
11522695
CHEMBL354494 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:status |
investigational drug
|
| gptkbp:target |
gptkb:AKT1
gptkb:AKT2 gptkb:AKT3 |
| gptkbp:bfsParent |
gptkb:Epac
gptkb:EPAC1 |
| gptkbp:bfsLayer |
7
|